Sellas Life Sciences Group (SLS) said Tuesday that group three data showed that tambiciclib topped the benchmark for median overall survival in the ongoing phase 2 relapsed/refractory acute myeloid leukemia study.
The median overall survival for all patients in the group was 8.8 months and 8.9 months for patients with AML-myelodysplasia-related changes or AML-MRC, exceeding the historical benchmark of 2.5 months, the company said.
The overall response rate in all evaluable patients was 46% in all group three patients and 67% in AML-MRC patients, surpassing the targeted 20% ORR, the company added.
The company said phase 2 trial continues in expansion groups four and five.
Shares of Sellas Life Sciences rose 5.8% in recent trading.
Price: 1.10, Change: +0.06, Percent Change: +5.77
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。